Travere Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 6, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Arrangements
During the fiscal quarter ended March 31, 2024, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted, modified orterminated the “Rule 10b5-1 trading arrangements” or “non-Rule 10b5-1 trading arrangements,” as those terms are defined in Regulation S-K, Item 408, set forth below:
Trading Arrangements Adopted:
| Name & Title | Date Adopted | Character of Trading Arrangement (1) | Aggregate Number of Shares of Common Stock to be Sold Pursuant to Trading Arrangement | Expiration Date (2) |
|---|---|---|---|---|
| Eric Dube, Ph.D.,President and Chief Executive Officer | March 15, 2024 | Rule 10b5-1 Trading Arrangement | Up to 131,775 shares | July 15, 2025 |
| Christopher Cline,Chief Financial Officer | March 15, 2024 | Rule 10b5-1 Trading Arrangement | Up to 55,000 shares (3) | July 15, 2025 |
| Peter Heerma,Chief Commercial Officer | March 15, 2024 | Rule 10b5-1 Trading Arrangement | Up to 14,493 shares | July 15, 2025 |
| Jula Inrig, M.D.,Chief Medical Officer | March 15, 2024 | Rule 10b5-1 Trading Arrangement | Up to 30,796 shares | July 15, 2025 |
| Elizabeth E. Reed,SVP, General Counsel and Corporate Secretary | March 15, 2024 | Rule 10b5-1 Trading Arrangement | Up to 147,115 shares (4) | July 15, 2025 |
| William E. Rote, Ph.D.,SVP, Research & Development | March 15, 2024 | Rule 10b5-1 Trading Arrangement | Up to 27,371 shares | July 15, 2025 |
| 1 | Each trading arrangement marked as a “Rule 10b5-1 Trading Arrangement” is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act (the “Rule”). |
| 2 | Each trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all sales and (b) the date listed in the table. Each trading arrangement marked as a “Rule 10b5-1 Trading Arrangement” only permits transactions upon expiration of the applicable mandatory cooling-off period under the Rule. |
| 3 | Consists of shares underlying stock options expiring in 2024 and 2025. |
| 4 | Includes shares underlying stock options expiring in January 2027. |
Trading Arrangements Modified:
On March 17, 2023, Jeffrey Meckler, amember of our Board of Directors, adopted a Rule 10b5-1 Trading Arrangement with a duration through October 8, 2024 (the “Meckler Trading Plan”) intended to satisfy the affirmative defense of the Rule, which provides for the sale by Mr. Meckler of up to 40,000 shares of our common stock underlying a stock option granted to Mr. Meckler on October 8, 2014 which will expire on October 8, 2024. On March 15, 2024, Mr. Meckler entered into an amendment to the Meckler Trading Plan, which under the Rule constitutes the termination of the Meckler Trading Plan and the adoption of a new Rule 10b5-1 Trading Arrangement (the “Amended Meckler Trading Plan”). The Amended Meckler Trading Plan continues to cover the sale of up to 40,000 shares of our common stock underlying a stock option granted to Mr. Meckler on October 8, 2014 and has an expiration date of October 8, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.